Plain-English translation of NCT05412589 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a three-part treatment combination for people with advanced liver cancer (stage III). The combination includes mFOLFOX7 chemotherapy given through a vein, plus two additional medications: Camrelizumab (which helps your immune system fight cancer) and Apatinib (which blocks the blood supply to tumors). Researchers hope this combination will work better than current standard treatments.
Earlier studies showed that combining immune-boosting drugs with medications that stop tumors from growing had promising results for advanced liver cancer. However, the delivery method used in those studies had drawbacks—it was technically difficult, expensive, and uncomfortable for patients. This trial is testing whether the same medication combination can work just as well when given through a regular vein instead.
You likely qualify if…
You likely don't qualify if…
You would receive the three-part medication combination on a regular schedule through an intravenous (IV) line in your vein. You would attend visits to receive the medications, have blood tests and imaging scans to check how the cancer is responding, and be monitored for any side effects. The trial involves 35 people total, and you would need to commit to the full treatment schedule and follow-up visits.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment target
~35 participants
Started
June 2022
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yunxiuxiu Xu, MD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.